International Clinical Trial: Exploratory Study of Transarterial Chemoembolization (TACE) Combined with Eparlitozoviril Antibody and Lenvatinib for Intermediate-to-Advanced Hepatocellular Carcinoma

Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117109) titled 'Exploratory Study of Transarterial Chemoembolization (TACE) Combined with Eparlitozoviril Antibody and Lenvatinib for Intermediate-to-Advanced Hepatocellular Carcinoma' on Jan. 20.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The Affiliated Hospital of Xuzhou Medical University

Condition: Hepatocellular carcinoma

Intervention: Trial group:QL1706 combined with lenvatinib is administered (one treatment cycle every 3 weeks), followed by as-needed TACE (total of 2-3 sessions), until disease progression, intolerance, initiation of other anticancer therapy, loss to follow-up, death, ...